What happened with TLSA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Tiziana Life Sciences is a drug developer whose clinical programs include Foralumab, an antibody being studied for neurological diseases such as non-active secondary progressive multiple sclerosis and Alzheimer’s disease. Its proposed approach is to use regulatory T cells, which help control immune responses, to reduce inflammation in the nervous system.
The company has no medicines approved for sale and generates no product-sales revenue. It funds its work mainly by raising capital from investors and needs additional financing to continue development. Before it can sell a medicine, clinical trials must establish its safety and effectiveness and regulators must approve it. Future sales would depend substantially on insurers, government programs and other healthcare payors covering treatment costs. Tiziana has no sales team and plans to build commercial capabilities or use third parties if a medicine is approved.
Development also depends on licensed technology from partners including Novimmune and Lonza, and on outside clinical researchers and manufacturers. Each drug candidate relies on a single contract manufacturer, with no backup source. Tiziana must maintain its licenses and meet their payment obligations to retain the rights needed for development and commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tiziana’s prospects depend on foralumab trial results and continued financing, with Roche’s approved and investigational progressive-MS treatments also shaping the competition.
Immunic competes with Tiziana in progressive multiple sclerosis, developing the oral drug vidofludimus calcium while Tiziana develops the antibody foralumab. Watch vidofludimus results in progressive disease, distinct from its Phase 3 program in relapsing MS; Immunic had no product-sales revenue through December 2025.
Alterity Therapeutics competes with Tiziana for treating multiple system atrophy, where Tiziana is developing foralumab as a nasal spray. Alterity’s clinical results in that disease are the relevant comparison, rather than its broader Parkinson’s research.
Quantum Biopharma’s Lucid-MS targets the same progressive-MS market as Tiziana’s foralumab, but aims to address damage to nerve insulation rather than modulate immunity. Watch whether Lucid-MS advances beyond the animal-model findings Quantum reports on preventing that damage and supporting repair.
Sanofi’s tolebrutinib competes with Tiziana’s foralumab in progressive multiple sclerosis. For Tiziana holders, tolebrutinib’s Phase 3 results are more directly relevant than Sanofi’s wider medicines and vaccines business.
Kyverna Therapeutics’ KYV-101 and Tiziana’s foralumab are competing attempts to treat multiple sclerosis by modulating immunity, using CAR-T cell therapy and an antibody respectively. Watch KYV-101’s development in MS; Kyverna had no approved products or product-sales revenue through December 2025.
TG Therapeutics already sells the MS antibody BRIUMVI, but its adult relapsing-MS patients differ from the non-active secondary progressive-MS group Tiziana targets with foralumab. TG’s U.S. BRIUMVI sales show commercial demand in that adjacent patient group, not demand for Tiziana’s intended use.
Novartis already markets siponimod for progressive multiple sclerosis, putting an approved treatment in the field Tiziana is pursuing with foralumab. Watch siponimod rather than Novartis’s total drug sales, while keeping the differences in eligible patients in view.
Tiziana relies on rights to use Bristol Myers Squibb intellectual property, obtained through NovImmune sublicenses, to develop foralumab and IL-6R antibodies; these carry milestone and potential royalty obligations. Tiziana retains development control, but inability to fund license payments could cost it the rights to develop or commercialize affected drugs.
Novartis AG earningsNVS
Novartis's report will show whether siponimod, an approved treatment for some people with progressive multiple sclerosis, is gaining use, offering a demand signal for the field where Tiziana is developing foralumab.
Look for siponimod use, not Novartis's total drug sales. Rising use would show that patients and doctors are adopting an approved treatment for some forms of progressive multiple sclerosis, but would not establish demand among Tiziana's intended patients. Falling use would make the commercial demand signal in this field weaker; the different eligible patient groups still matter.
